Alobresib
Small moleculeexperimental
Clinical trial activity
3 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Mar 16, 2015 (NCT02392611)
Timeline
2010s
- Jan 1, 2015
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Unspecified targetUnclear
unclear
Chemistry & pharmacology
Loading structure…
SMILES
Cc1noc(C)c1-c1cc(C(O)(c2ccccn2)c2ccccn2)c2nc(C3CC3)[nH]c2c1- Mol. weight
- 437.5 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3982690 ↗
Also known as
- gs-5829
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02983604 | Phase 1/Phase 2 (Phase 2) | Jan 11, 2017 | Gilead Sciences |
| NCT02607228 | Phase 1/Phase 2 (Phase 2) | Dec 8, 2015 | Gilead Sciences |
| NCT02392611 | Phase 1 | Mar 16, 2015 | Gilead Sciences |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Gilead Sciences | For profit | 3 | 3 | 2 | 2015 |
1 organizations
Page 1 / 1